Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516585 | 0.91 | GAA (0.46) | GAANPC1RAB9ALMNAMAPT | |
| Meglitinide SCHEMBL29829482 | 0.71 | DNMT3A (0.78) | GAA | |
| Meglitinide SCHEMBL37926 | 0.71 | DNMT3A (0.78) | GAA | |
| SCHEMBL16562164 | 0.71 | RAB9A (0.67) | GAANPC1RAB9ALMNAMAPT | |
| SCHEMBL8307439 | 0.70 | DAO (0.42) | RAB9ALMNAMAPK1 | |
| SCHEMBL27883373 | 0.70 | USP2 (0.70) | GAANR1H4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4304151 | 0.69 | PTGER4 (0.66) | GAANPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL8548802 | 0.68 | NPC1 (0.72) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL28489579 | 0.68 | NPC1 (0.72) | NPC1RAB9ALMNASMN1; SMN2MTNR1B | |
| SCHEMBL17916743 | 0.68 | RAB9A (0.69) | GAANPC1RAB9ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283349-B2 | Fungicide N-(3-phenylpropyl) carboxamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-10-09 | — | — | US | claimed |
| US-20100087494-A1 | FUNGICIDE N-(3-PHENYLPROPYL) CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-04-08 | — | — | US | claimed |
| EP-2125740-A1 | FUNGICIDE N-(3-PHENYLPROPYL)CARBOXAMIDE DERIVATIVES | Bayer CropScience SA (FR) | 2009-12-02 | — | — | EP | claimed |
| WO-2008101976-A1 | FUNGICIDE N-(3-PHENYLPROPYL)CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-08-28 | — | — | WO | claimed |
| US-8283349-B2 | Fungicide N-(3-phenylpropyl) carboxamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20100087494-A1 | FUNGICIDE N-(3-PHENYLPROPYL) CARBOXAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| EP-2125740-A1 | FUNGICIDE N-(3-PHENYLPROPYL)CARBOXAMIDE DERIVATIVES | Bayer CropScience SA (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101976-A1 | FUNGICIDE N-(3-PHENYLPROPYL)CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087494-A1 | FUNGICIDE N-(3-PHENYLPROPYL) CARBOXAMIDE DERIVATIVES | CYP51A1, CYP1A2, CYP3A7 | GAA 55/4885NR1H4 2418/4885NPC1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.